Eiger BioPharmaceuticals Inc. received approval Wednesday to select a $30 million base offer for its Zokinvy drug and use cash collateral after a Texas bankruptcy judge dismissed objections to the relief.
https://www.law360.com/bankruptcy-authority/articles/1820446
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.